SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
World game at war: why some European nations have threatened a World Cup boycott 
CAMBRIDGE, Mass., April 24, 2018 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2018 financial results and business highlights.
| What: | Vericel Corporation First-Quarter 2018 Earnings Call | |
| When: | Tuesday, May 8, 2018 at 8:30am (EDT) | |
| Where: | http://investors.vcel.com/events-presentations | |
| How: | The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events-presentations. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. |
To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation first-quarter 2018 earnings call. If calling from outside the U.S., please use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events-presentations until May 8, 2019. A replay of the call will also be available until 11:30am (EDT) on May 13, 2018 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 1564056.
About Vericel Corporation
Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.
VCEL-fin
Global Media Contacts:
David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
[email protected]
Karen Chase
Russo Partners LLC
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)
[email protected]
Investor Contacts:
Chad Rubin
Solebury Trout
[email protected]
+1 (646) 378-2947
Lee Stern
Solebury Trout
[email protected]
+1 (646) 378-2922
